Benzimidazole-Coordinated Copper(II) Complexes as Effectual Chemotherapeutics against Malignancy

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Cancer Research

Background:

• Cancer is a leading cause of mortality, with drug resistance posing a significant challenge.
• Benzimidazole derivatives show promise in cancer therapy but face limitations like low bioavailability and toxicity.
• Innovative therapeutic agents targeting malignant cells are crucial for advancing cancer treatment.

Purpose of the Study:

• To synthesize and characterize novel copper(II) complexes with benzimidazole ligands.
• To evaluate the anticancer activity and mechanism of action of these complexes.
• To explore the potential of these complexes as new anticancer agents.

Main Methods:

• Synthesis of benzimidazole ligands (L and L') and their copper(II) complexes (1 and 2).
• Structural characterization using X-ray crystallography and mass spectrometry.
• In vitro evaluation of cytotoxicity, cell cycle, apoptosis, and DNA binding against cancer cell lines.

Main Results:

• Two stable copper(II) complexes, one mononuclear (1) and one dinuclear (2), were successfully synthesized.
• Complex 2 exhibited higher stability than complex 1.
• Both complexes demonstrated significant cytotoxicity against mouse and human cancer cell lines, inducing apoptosis via DNA intercalation.

Conclusions:

• The synthesized copper(II)-benzimidazole complexes show substantial anticancer potential.
• These complexes effectively inhibit cancer cell proliferation and induce apoptosis.
• Further development of these compounds could lead to novel therapeutic strategies for cancer treatment.